domperidone has been researched along with Pituitary Neoplasms in 45 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the usefulness of the domperidone test for the difficult diagnosis between functional and tumoral hyperprolactinemia." | 9.10 | Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. ( Azaretzky, M; Boquete, HR; Fideleff, G; Fideleff, HL; Giaccio, AV; Honfi, M; Pujol, AB; Suárez, MG, 2003) |
| "Eighty-four patients (10 male, 74 female) whose investigation of hyperprolactinaemia included a domperidone test and high resolution pituitary MRI." | 7.69 | An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia. ( Bevan, JS; Robb, OJ; Sawers, HA; Shaw, J; Strachan, FM; Walmsley, D, 1997) |
| "Administration of a dopamine (DA) antagonist, domperidone, increased circulating levels of LH in hyperprolactinaemic-amenorrhoeic women with pituitary microadenomas but not in normal women in the early follicular phase of the menstrual cycle." | 7.67 | Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas. ( Kato, K; Seki, K, 1988) |
| "These results suggestthat in PES with prolactinoma the inhibiting dopaminergic tone is increased on the thyrotropic cells and reduced on the lactotropic cells in PES with elevated PRL and that some patients with PES might bear a microprolactinoma in the bottom of the sella which remained undetected by the CT scan." | 5.29 | TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome. ( Attali, JR; Combes, ME; Perret, G; Valensi, P, 1996) |
| "When domperidone was injected at the termination of DA infusion, the postinhibitory increases were significantly enhanced in either PRL-oma or normal subjects." | 5.27 | Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma. ( Goh, M; Hanew, K; Murakami, O; Sasaki, A; Sato, S; Shimizu, Y; Yoshinaga, K, 1985) |
| "The aim of this study was to evaluate the usefulness of the domperidone test for the difficult diagnosis between functional and tumoral hyperprolactinemia." | 5.10 | Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. ( Azaretzky, M; Boquete, HR; Fideleff, G; Fideleff, HL; Giaccio, AV; Honfi, M; Pujol, AB; Suárez, MG, 2003) |
| " Because D2(High) receptors have not yet been detected in intact cells, we used [(3)H]domperidone to detect D2(High) sites in intact rat anterior pituitary adenoma culture cells." | 3.74 | Dopamine D2(High) receptors on intact cells. ( Seeman, P, 2008) |
| "Eighty-four patients (10 male, 74 female) whose investigation of hyperprolactinaemia included a domperidone test and high resolution pituitary MRI." | 3.69 | An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia. ( Bevan, JS; Robb, OJ; Sawers, HA; Shaw, J; Strachan, FM; Walmsley, D, 1997) |
| "Administration of a dopamine (DA) antagonist, domperidone, increased circulating levels of LH in hyperprolactinaemic-amenorrhoeic women with pituitary microadenomas but not in normal women in the early follicular phase of the menstrual cycle." | 3.67 | Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas. ( Kato, K; Seki, K, 1988) |
| "To verify the diagnostic capacity of some dynamic tests of the prolactin (Prl) secretion, the findings obtained by high-resolution computed tomography (CT) were compared with results obtained from tests using nomifensine (NOM) domperidone (DOM) and thyrotrophin-releasing hormone (TRH) in 72 patients with pathological hyperprolactinaemia." | 3.67 | Comparison between pituitary computed tomographic findings and tests of hypothalamo-pituitary function in 72 patients with hyperprolactinaemia. ( Bianchi, SD; Camanni, F; Ciccarelli, E; Gatti, G; Ghigo, E; Massara, F; Molinatti, GM; Müller, EE, 1986) |
| " Preoperatively in patients with prolactinomas (n = 33) the TSH response to domperidone decreased with increasing adenoma size." | 3.67 | The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery. ( Hall, R; Howell, S; John, R; Peters, JR; Richards, SH; Salvador, J; Scanlon, MF; Thomas, JP; Williams, ED, 1986) |
| " Twenty-six women diagnosed by dynamic tests and radiologic examination as having PRL-secreting adenoma were treated surgically (15) or with bromocriptine (11) and their condition was evaluated one to three years later by TRH, nomifensine, and domperidone tests." | 3.67 | Prolactin secretion after surgery or bromocriptine treatment of prolactinoma. ( D'Antona, N; Danero, S; De Leo, V; Genazzani, AR; Petraglia, F; Sardelli, S, 1987) |
| "The basal prolactin (PRL) levels on five different days, the PRL responses to thyrotropin-releasing hormone and to domperidone, and the thyroid-stimulating hormone (TSH) responses to domperidone were studied in 75 regularly menstruating women and 44 patients with moderate hyperprolactinemia." | 3.67 | Is idiopathic hyperprolactinemia a transitional stage toward prolactinoma? ( Afonso, AM; Ferreira, JM; Pereira, MC; Santos, MA; Sobrinho, LG; Sousa, MF, 1987) |
| "The response to domperidone (a dopamine blocking agent) of serum prolactin (PRL) levels was compared in 3 patients with amenorrhea-galactorrhea without evidence of a pituitary tumor, 23 patients with prolactinomas (10 cases with histologic confirmation), 7 patients with histologically verified large nonfunctioning pituitary adenomas with normal or moderately elevated basal PRL levels, and 6 patients with histologically verified craniopharyngiomas (3 with normal basal PRL levels and 3 with elevated PRL levels)." | 3.67 | Dysfunction of dopaminergic regulation of prolactin in patients with functioning and nonfunctioning pituitary adenomas and craniopharyngiomas. ( Cornejo, J; Garza-Flores, J; Martinez-Campos, A; Velasco, F, 1985) |
| "Fifteen normal menstruating women in the early follicular phase of their menstrual cycle, fifteen patients with prolactin secreting adenomas, two patients with a suprahypophysial lesion and an hyperprolactinemia, underwent a dopamine infusion (4 micrograms/kg/mn for four hours and an orally administration of domperidone (40 mg)." | 3.66 | [Kinetics of prolactinemia after withdrawal of dopamine perfusion and during the administration of domperidone. Normal and hyperprolactinemic subjects (prolactinomas and suprahypophyseal lesions)]. ( Bercovici, JP; Besson, G; Caroff, J; Khoury, S; Tater, D, 1983) |
| " The intensity of dopamine (DA) effects on the pituitary around the adenoma was evaluated by measuring thyroid stimulating hormone (TSH) responses to intravenous injection of domperidone (10 mg) a new DA receptor blocking drug that does not penetrate the blood-brain barrier." | 3.66 | Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. ( Cook, DB; Gomez-Pan, A; Hall, R; Lewis, M; McGregor, AM; Rodriguez-Arnao, MD; Scanlon, MF; Weightman, D, 1981) |
| "These results suggestthat in PES with prolactinoma the inhibiting dopaminergic tone is increased on the thyrotropic cells and reduced on the lactotropic cells in PES with elevated PRL and that some patients with PES might bear a microprolactinoma in the bottom of the sella which remained undetected by the CT scan." | 1.29 | TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome. ( Attali, JR; Combes, ME; Perret, G; Valensi, P, 1996) |
| "Microprolactinoma is a particular pathological situation characterized by the presence of increased hypothalamic dopaminergic tone reactive to tumoral hyperprolactinemia." | 1.28 | Thyrotropin alpha- and beta-subunit responses to thyrotropin-releasing hormone and domperidone in normal subjects and in patients with microprolactinomas. ( Beck-Peccoz, P; Conti, A; Faglia, G; Medri, G; Persani, L, 1991) |
| "Baclofen was unable to significantly rise serum PRL levels in healthy subjects and in patients affected by prolactinoma and furthermore did not interfere with PRL rise domperidone induced." | 1.27 | [Prolactin after baclofen in healthy subjects and prolactinoma patients]. ( Carletti, P; Ferretti, GF; Marchesi, GF; Morosini, PP; Nardi, B; Sarzani, R, 1985) |
| "The normality of the GH-ACTH-secreting pituitary tumors and hypothalamic tumor responses to TRH is one more factor in differentiating these from prolactinomas." | 1.27 | Evidence of abnormal dopaminergic control of prolactin in patients with hypothalamic and pituitary tumors. ( Almoguera, I; Cabranes, JA; Charro, AL; del Olmo, J; Pablos, I; Prensa, A, 1986) |
| "When domperidone was injected at the termination of DA infusion, the postinhibitory increases were significantly enhanced in either PRL-oma or normal subjects." | 1.27 | Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma. ( Goh, M; Hanew, K; Murakami, O; Sasaki, A; Sato, S; Shimizu, Y; Yoshinaga, K, 1985) |
| "Domperidone did not increase PRL in about a third of acromegalic patients, while TRH increased PRL in the all normoprolactinemic acromegalic patients." | 1.27 | Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia. ( Ibayashi, H; Ikuyama, S; Karashima, T; Kato, K; Muta, K; Sekiya, K, 1985) |
| " The direct control of GH secretion at the pituitary level has been observed using human GH-secreting pituitary adenomas in organ culture, but no dose-response relationship between DA and GH inhibition was demonstrated." | 1.26 | Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system. ( Brandi, AM; Bression, D; Le Dafniet, M; Nousbaum, A; Peillon, F; Racadot, J, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (80.00) | 18.7374 |
| 1990's | 6 (13.33) | 18.2507 |
| 2000's | 3 (6.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fideleff, HL | 1 |
| Azaretzky, M | 1 |
| Boquete, HR | 1 |
| Pujol, AB | 1 |
| Honfi, M | 1 |
| Suárez, MG | 1 |
| Fideleff, G | 1 |
| Giaccio, AV | 1 |
| Pinto, LP | 1 |
| Hanna, FW | 1 |
| Evans, LM | 1 |
| Davies, JS | 1 |
| John, R | 2 |
| Scanlon, MF | 6 |
| Seeman, P | 1 |
| Clayton, RN | 1 |
| Bailey, LC | 1 |
| Rowe, RC | 1 |
| Cowden, EA | 1 |
| Faiman, C | 1 |
| Friesen, HG | 1 |
| De Leo, V | 5 |
| D'Ambrogio, G | 1 |
| De Leo, M | 2 |
| Franchi, F | 1 |
| Inaudi, P | 1 |
| La Rosa, R | 1 |
| D'Antona, N | 2 |
| Genazzani, AR | 4 |
| Camanni, F | 7 |
| Ghigo, E | 5 |
| Ciccarelli, E | 4 |
| Massara, F | 5 |
| Campagnoli, C | 2 |
| Molinatti, G | 1 |
| Müller, EE | 8 |
| Chanson, P | 1 |
| Orgiazzi, J | 1 |
| Derome, PJ | 1 |
| Bression, D | 3 |
| Jedynak, CP | 1 |
| Trouillas, J | 1 |
| Legentil, P | 1 |
| Racadot, J | 3 |
| Peillon, F | 3 |
| Cavagnini, F | 1 |
| Martinez-Campos, A | 2 |
| Maraschini, C | 1 |
| Giovannini, P | 1 |
| Novelli, A | 2 |
| Pogliano, G | 1 |
| Bertagna, A | 1 |
| Rodriguez-Arnao, MD | 3 |
| Peters, JR | 3 |
| Foord, SM | 2 |
| Dieguez, C | 2 |
| Edwards, C | 2 |
| Gomez-Pan, A | 2 |
| Hall, R | 4 |
| Newcombe, RG | 1 |
| Bercovici, JP | 1 |
| Khoury, S | 1 |
| Tater, D | 1 |
| Besson, G | 1 |
| Caroff, J | 1 |
| McGregor, AM | 1 |
| Weightman, D | 1 |
| Lewis, M | 1 |
| Cook, DB | 2 |
| Casanueva, F | 1 |
| Cocchi, D | 2 |
| Locatelli, V | 1 |
| Flauto, C | 1 |
| Zambotti, F | 1 |
| Bestetti, G | 1 |
| Rossi, GL | 2 |
| Müller, E | 1 |
| Martra, M | 1 |
| Dolfin, GC | 1 |
| Molinatti, GM | 3 |
| De Gennes, JL | 2 |
| Turpin, G | 2 |
| Heshmati, HM | 1 |
| Carayon, A | 1 |
| Brandi, AM | 2 |
| Nousbaum, A | 2 |
| Le Dafniet, M | 1 |
| Massafra, C | 1 |
| La Marca, S | 1 |
| Venturi, C | 1 |
| Urbani, TM | 1 |
| Martres, MP | 1 |
| Cesselin, F | 1 |
| Valensi, P | 1 |
| Combes, ME | 1 |
| Perret, G | 1 |
| Attali, JR | 1 |
| Sawers, HA | 1 |
| Robb, OJ | 1 |
| Walmsley, D | 1 |
| Strachan, FM | 1 |
| Shaw, J | 1 |
| Bevan, JS | 3 |
| Lu, F | 1 |
| Wu, H | 1 |
| Zhang, K | 1 |
| Li, D | 1 |
| Webster, J | 1 |
| Page, MD | 1 |
| Richards, SH | 2 |
| Douglas-Jones, AG | 1 |
| Persani, L | 1 |
| Beck-Peccoz, P | 1 |
| Medri, G | 1 |
| Conti, A | 3 |
| Faglia, G | 4 |
| Miola, C | 1 |
| Gandini, G | 1 |
| Burke, CW | 1 |
| Esiri, MM | 1 |
| Adams, CB | 1 |
| Ballabio, M | 1 |
| Nissim, M | 2 |
| Scherrer, H | 1 |
| Vermet, M | 1 |
| Morosini, PP | 1 |
| Carletti, P | 1 |
| Sarzani, R | 1 |
| Ferretti, GF | 1 |
| Marchesi, GF | 1 |
| Nardi, B | 1 |
| Cabranes, JA | 1 |
| Almoguera, I | 1 |
| del Olmo, J | 1 |
| Prensa, A | 1 |
| Pablos, I | 1 |
| Charro, AL | 1 |
| Seki, K | 1 |
| Kato, K | 2 |
| Bianchi, SD | 1 |
| Gatti, G | 1 |
| Salvador, J | 1 |
| Howell, S | 1 |
| Williams, ED | 1 |
| Thomas, JP | 1 |
| Petraglia, F | 1 |
| Sardelli, S | 1 |
| Danero, S | 1 |
| Pereira, MC | 1 |
| Sobrinho, LG | 1 |
| Afonso, AM | 1 |
| Ferreira, JM | 1 |
| Santos, MA | 1 |
| Sousa, MF | 1 |
| Togni, E | 1 |
| Travaglini, P | 2 |
| Muratori, M | 1 |
| Moriondo, P | 1 |
| Prescott, RW | 1 |
| Johnston, DG | 1 |
| Taylor, PK | 1 |
| Haigh, J | 1 |
| Weightman, DR | 1 |
| Hall, K | 1 |
| Hanew, K | 1 |
| Sato, S | 1 |
| Sasaki, A | 1 |
| Goh, M | 1 |
| Shimizu, Y | 1 |
| Murakami, O | 1 |
| Yoshinaga, K | 1 |
| Massobrio, M | 1 |
| Peñalva, A | 1 |
| Torpia, R | 1 |
| Israel, JM | 1 |
| Jaquet, P | 1 |
| Vincent, JD | 1 |
| Woodhead, S | 1 |
| Sekiya, K | 1 |
| Karashima, T | 1 |
| Ikuyama, S | 1 |
| Muta, K | 1 |
| Ibayashi, H | 1 |
| Cornejo, J | 1 |
| Garza-Flores, J | 1 |
| Velasco, F | 1 |
2 trials available for domperidone and Pituitary Neoplasms
| Article | Year |
|---|---|
Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test.
Topics: Adenoma; Adolescent; Child; Domperidone; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; M | 2003 |
Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Topics: Adenoma; Adolescent; Adult; Circadian Rhythm; Domperidone; Dopamine; Female; Humans; Hypothalamus; M | 1983 |
43 other studies available for domperidone and Pituitary Neoplasms
| Article | Year |
|---|---|
The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia.
Topics: Adult; Domperidone; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary | 2003 |
Dopamine D2(High) receptors on intact cells.
Topics: Adenoma; Animals; Binding, Competitive; Corpus Striatum; Domperidone; Dopamine Antagonists; Pituitar | 2008 |
Dopamine agonist- and antagonist-induced modulation of pituitary gonadotrophin releasing hormone receptors are independent of changes in serum prolactin.
Topics: Animals; Bromocriptine; Domperidone; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Ho | 1984 |
Correlation of Nb2 bioassay and radioimmunoassay values for human serum prolactin.
Topics: Adult; Animals; Biological Assay; Cell Division; Cell Line; Domperidone; Female; Humans; Lymphoma; M | 1983 |
[Hyperprolactinemia in chronic renal insufficiency: an interesting model of hypothalamo-hypophyseal dysfunction].
Topics: Adult; Bromocriptine; Domperidone; Female; Humans; Hypothalamo-Hypophyseal System; Kidney Failure, C | 1983 |
Defective regulation of prolactin secretion after successful removal of prolactinomas.
Topics: Adenoma; Adult; Domperidone; Female; Humans; Male; Nomifensine; Pituitary Neoplasms; Pregnancy; Prol | 1983 |
Paradoxical response of thyrotropin to L-dopa and presence of dopaminergic receptors in a thyrotropin-secreting pituitary adenoma.
Topics: Adenoma; Adult; Domperidone; Female; Humans; In Vitro Techniques; Levodopa; Pituitary Neoplasms; Rec | 1984 |
Dynamic testing of prolactin and growth hormone secretion in patients with neuroendocrine disorders.
Topics: Acromegaly; Adolescent; Adult; Aged; Brain; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Domperidone; Fem | 1984 |
Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia.
Topics: Adult; Domperidone; Ethinyl Estradiol; Female; Follicular Phase; Humans; Pituitary Neoplasms; Prolac | 1984 |
[Kinetics of prolactinemia after withdrawal of dopamine perfusion and during the administration of domperidone. Normal and hyperprolactinemic subjects (prolactinomas and suprahypophyseal lesions)].
Topics: Adenoma; Adult; Domperidone; Dopamine; Female; Follicular Phase; Humans; Kinetics; Pituitary Disease | 1983 |
Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.
Topics: Adenoma; Adolescent; Adult; Benzimidazoles; Domperidone; Female; Growth Hormone; Humans; Hydrocortis | 1981 |
Defective central nervous system dopaminergic function in rats with estrogen-induced pituitary tumors, as assessed by plasma prolactin concentrations.
Topics: Animals; Brain; Bromocriptine; Domperidone; Dopamine; Estradiol; Female; Hypothalamus; Median Eminen | 1982 |
Reciprocal pattern of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia.
Topics: Adolescent; Adult; Domperidone; Female; Humans; Pituitary Neoplasms; Postpartum Period; Pregnancy; P | 1983 |
[Progress in the hormonal detection of pituitary prolactin adenoma].
Topics: Adenoma; Bromocriptine; Domperidone; Humans; Metoclopramide; Nomifensine; Pituitary Neoplasms; Prola | 1982 |
Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system.
Topics: Adenoma; Apomorphine; Domperidone; Dopamine; Dose-Response Relationship, Drug; Growth Hormone; Human | 1982 |
[Indirect dopamine agonists and direct dopamine antagonists in the diagnosis of hyperprolactinemia].
Topics: Adenoma; Adult; Domperidone; False Negative Reactions; False Positive Reactions; Female; Humans; Iso | 1982 |
Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone.
Topics: Adenoma; Adult; Benzimidazoles; Domperidone; Female; Humans; Isoquinolines; Male; Menstruation; Midd | 1981 |
Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study.
Topics: Adenoma; Adolescent; Adult; Aged; Benzimidazoles; Binding, Competitive; Cell Membrane; Domperidone; | 1980 |
TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome.
Topics: Adult; Domperidone; Empty Sella Syndrome; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pit | 1996 |
An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia.
Topics: Adolescent; Adult; Domperidone; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Magnetic R | 1997 |
[Domperidone and hyperprolactinemia].
Topics: Adult; Domperidone; Female; Gastrointestinal Agents; Humans; Hyperprolactinemia; Middle Aged; Pituit | 1998 |
Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
Topics: Adult; Domperidone; Female; Follow-Up Studies; Humans; Hypophysectomy; Male; Middle Aged; Neoplasm R | 1992 |
Thyrotropin alpha- and beta-subunit responses to thyrotropin-releasing hormone and domperidone in normal subjects and in patients with microprolactinomas.
Topics: Adult; Domperidone; Dopamine; Female; Follicle Stimulating Hormone; Glycoprotein Hormones, alpha Sub | 1991 |
Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy.
Topics: Adenoma; Adrenalectomy; Adult; Domperidone; Dopamine Antagonists; Female; Follow-Up Studies; Humans; | 1990 |
Studies of two thyrotrophin-secreting pituitary adenomas: evidence for dopamine receptor deficiency.
Topics: Adenoma; Adult; Biological Assay; Bromocriptine; Chromatography, Gel; Domperidone; Female; Humans; I | 1989 |
[Combination of domperidone and bromocriptine in the treatment of prolactinoma].
Topics: Bromocriptine; Domperidone; Drug Therapy, Combination; Humans; Pituitary Neoplasms; Prolactin | 1986 |
[Prolactin after baclofen in healthy subjects and prolactinoma patients].
Topics: Adult; Baclofen; Cimetidine; Domperidone; Dopamine; Drug Interactions; Female; Humans; Hypothalamo-H | 1985 |
Evidence of abnormal dopaminergic control of prolactin in patients with hypothalamic and pituitary tumors.
Topics: Adrenocorticotropic Hormone; Domperidone; Female; Growth Hormone; Humans; Hypothalamic Neoplasms; Ma | 1986 |
Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas.
Topics: Adenoma; Adult; Domperidone; Female; Follicular Phase; Humans; Hyperprolactinemia; Luteinizing Hormo | 1988 |
Comparison between pituitary computed tomographic findings and tests of hypothalamo-pituitary function in 72 patients with hyperprolactinaemia.
Topics: Adenoma; Adolescent; Adult; Domperidone; Female; Humans; Hyperprolactinemia; Hypothalamo-Hypophyseal | 1986 |
The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.
Topics: Adenoma; Adult; Aged; Domperidone; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Postopera | 1986 |
Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
Topics: Adenoma; Adult; Bromocriptine; Domperidone; Female; Humans; Hypophysectomy; Nomifensine; Pituitary N | 1987 |
Is idiopathic hyperprolactinemia a transitional stage toward prolactinoma?
Topics: Adult; Domperidone; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Thyrotropin; | 1987 |
Vasoactive intestinal polypeptide and dopamine: effect on prolactin secretion in normal women and patients with microprolactinomas.
Topics: Adolescent; Adult; Domperidone; Dopamine; Female; Humans; Pituitary Neoplasms; Prolactin; Vasoactive | 1987 |
Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Topics: Adenoma; Adolescent; Adult; Bromocriptine; Domperidone; Dose-Response Relationship, Drug; Female; Hu | 1985 |
The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia.
Topics: Adenoma; Adolescent; Adult; Blood Glucose; Diagnosis, Differential; Domperidone; Female; Humans; Ins | 1985 |
Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma.
Topics: Adenoma; Adolescent; Adult; Domperidone; Dopamine; Female; Humans; Hyperprolactinemia; Male; Pituita | 1985 |
Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia.
Topics: Adenoma; Adult; Animals; Binding, Competitive; Domperidone; Dopamine; Female; Humans; In Vitro Techn | 1985 |
Persistence of a defective tuberoinfundibular dopaminergic function in rats after long-term removal of oestrogen treatment. An in vivo study.
Topics: Adenoma; Animals; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Domperidone; Estradiol; Female; Hypothalam | 1985 |
The electrical properties of isolated human prolactin-secreting adenoma cells and their modification by dopamine.
Topics: Adenoma; Bromocriptine; Domperidone; Dopamine; Dose-Response Relationship, Drug; Electrophysiology; | 1985 |
Differential effects of acute DA receptor blockade with domperidone on LH and TSH release in patients with hyperprolactinemia.
Topics: Adult; Domperidone; Female; Humans; Luteinizing Hormone; Pituitary Neoplasms; Prolactin; Receptors, | 1985 |
Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia.
Topics: Acromegaly; Adult; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Domperidone; Female; Humans; Male; Middle | 1985 |
Dysfunction of dopaminergic regulation of prolactin in patients with functioning and nonfunctioning pituitary adenomas and craniopharyngiomas.
Topics: Adenoma; Adolescent; Adult; Amenorrhea; Craniopharyngioma; Domperidone; Dopamine; Female; Galactorrh | 1985 |